EDITORIAL CONTENT

• Beyond The VC Round: Creative Financing Strategies For Biotech's Bear Market

  Pretzel Therapeutics COO Baruch Harris shares creative financing strategies, from spinouts to non-dilutive funding, that keep biotech companies alive when VC capital dries up. Access the full conversation to build your capital roadmap.

• What Will It Actually Take To Build A Resilient Global Vaccine Supply Chain?

  U.S. funding cuts could leave 75 million children without routine vaccines. Five supply chain leaders explain what resilience actually requires and what's at stake if the sector fails to act.

• How Sanofi Navigates Regulatory CMC Across Global Markets

  Sanofi's Manda Pasarkar shares 20+ years of regulatory CMC expertise, covering FDA, EMA, and PMDA differences, CDMO partnerships, ICH guidelines, and AI's emerging role in global drug approvals.

• Tariffs, FDA Chaos, And BioSecure: How CDMOs Should Operate

  Tariffs, FDA workforce cuts, and a stalled BioSecure Act are reshaping CDMO strategy. Get the full policy breakdown to stress-test your supply chain planning now.

• 6 CMC Strategies Are Transforming Biologics Drug Development

  Sid Jain's two decades across Novartis, Regeneron, and Sanofi reveal six CMC strategies redefining how biologics reach the clinic, from CDMO selection to digital transformation pitfalls.

• Reshoring Pressure Meets Manufacturing Reality

  U.S. pharma can't reshore what domestic capacity can't absorb. Senior leaders from Takeda, Biogen, Eli Lilly, and others reveal why tariff pressure is colliding with a sterile fill-finish shortage, workforce gaps, and ADC capacity bottlenecks.

• CDMO Live Europe 2026: Partnerships For An Uncertain World

  112 pages of executive insight from CDMO Live Europe 2026: tariffs, geopolitics, supply resilience, AI in manufacturing, and why strategic partnerships remain aspirational for most.

• Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report

  Senior pharma leaders from Pfizer, Bayer, BioNTech and others debunk dual sourcing myths and reveal what separates strategic CDMO partnerships from transactional ones.